论文部分内容阅读
最近,日本科学家说,他们研究开发了一项攻克癌症的全新技术“养子免疫疗法”。科学家将癌症患者体内的免疫细胞——T细胞取出,通过特殊方法将其培养成一种叫做细胞伤害性T细胞(CTL)的状态,再注入病人体内。CTL能识别患者体内的癌细胞,并将其杀死。该疗法的成功之处在于,CTL在消灭癌细胞的同时,丝毫不损伤正常细胞,且没有任何副作用。而在此之前、大多数免疫疗法都对正常细胞有损害。
Recently, Japanese scientists said that they researched and developed a new technology “nigration immunotherapy” to overcome cancer. The scientists took the immune cells of cancer patients, T cells, and used a special method to cultivate them into a state called cell-damaging T cells (CTL) and then injected them into patients. CTL can identify cancer cells in patients and kill them. The success of this therapy is that CTL eliminates cancer cells at the same time without damaging normal cells and without any side effects. Prior to this, most immunotherapy had damage to normal cells.